Literature DB >> 31590930

Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission.

Daniel Aletaha1, Xin Wang2, Sheng Zhong3, Stefan Florentinus4, Kelly Monastiriakos5, Josef S Smolen6.   

Abstract

OBJECTIVES: In patients with rheumatoid arthritis (RA), remission may be assessed by various composite measures. We assessed achievement of remission as defined by Boolean criteria, Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), and 28-joint Disease Activity Score using C-reactive protein (DAS28[CRP]) and determined the components that limit patients in SDAI, CDAI, or DAS28(CRP) remission from achieving Boolean remission.
METHODS: The proportions of patients achieving Boolean, SDAI, CDAI, or DAS28(CRP) remission were calculated for 3 trials: PREMIER and OPTIMA in patients with early RA and DE019 in patients with established RA. At the first visit that remission was recorded during the first 52 weeks of the trial, the following were assessed: swollen/tender joint count at 28 and 66/68 joints, CRP, Patient's/Physician's Global Assessment (PGA/PhGA), SDAI, DAS28(CRP), and Health Assessment Questionnaire-Disability Index.
RESULTS: The majority of patients (61-66%) who achieved SDAI or CDAI remission also attained Boolean remission. Although DAS28(CRP) remission was most frequently attained, 74-77% of patients in DAS28(CRP) remission did not achieve Boolean remission. Compared with patients in Boolean remission, patients in SDAI or CDAI remission but not Boolean remission had higher PGA scores, while patients with DAS28(CRP) remission but not Boolean remission had higher joint counts, and PGA and PhGA scores.
CONCLUSIONS: Differences in PGA limit patients in SDAI/CDAI remission from meeting the Boolean remission criteria, suggesting that these criteria otherwise can be used interchangeably. In contrast, patients in DAS28(CRP) remission are limited by differences in multiple disease activity measures from achieving Boolean remission.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  Anti-TNF; Boolean remission; CDAI; Disease activity; Rheumatoid arthritis; SDAI

Mesh:

Substances:

Year:  2019        PMID: 31590930     DOI: 10.1016/j.semarthrit.2019.09.005

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  5 in total

1.  Prediction of disease flare by biomarkers after discontinuing biologics in patients with rheumatoid arthritis achieving stringent remission.

Authors:  Hideto Kameda; Ayako Hirata; Takaharu Katagiri; Yuto Takakura; Yuki Inoue; Sayaka Takenaka; Hideki Ito; Kennosuke Mizushina; Takehisa Ogura
Journal:  Sci Rep       Date:  2021-03-25       Impact factor: 4.379

2.  Clinical remission of rheumatoid arthritis in a multicenter real-world study in Asia-Pacific region.

Authors:  Xing Sun; Ru Li; Yueming Cai; Adeeba Al-Herz; Manjari Lahiri; Minhaj Rahim Choudhury; Rudy Hidayat; Bagus Putu Putra Suryana; Yuko Kaneko; Keishi Fujio; Nguyen Van Hung; Sapan Pandya; Leong Khai Pang; Wanruchada Katchamart; Keshav Raj Sigdel; Buddhi Paudyal; Pongthorn Narongroeknawin; Parawee Chevaisrakul; Feng Sun; Yu Lu; Carmen Ho; Swan Sim Yeap; Zhanguo Li
Journal:  Lancet Reg Health West Pac       Date:  2021-08-12

3.  Validity and risk of adopting PGA ≤ 2 as a remission criteria of Boolean in clinical practice in patient with rheumatoid arthritis.

Authors:  Ichiro Yoshii; Tatsumi Chijiwa; Naoya Sawada
Journal:  Sci Rep       Date:  2022-02-22       Impact factor: 4.379

4.  Abatacept downregulates Fcγ receptor I on circulating monocytes: a potential therapeutic mechanism in patients with rheumatoid arthritis.

Authors:  Ryosuke Fukue; Yuka Okazaki; Takahisa Gono; Masataka Kuwana
Journal:  Arthritis Res Ther       Date:  2022-08-13       Impact factor: 5.606

5.  Remission or Not Remission, That's the Question: Shedding Light on Remission and the Impact of Objective and Subjective Measures Reflecting Disease Activity in Rheumatoid Arthritis.

Authors:  Alen Brkic; Katarzyna Łosińska; Are Hugo Pripp; Mariusz Korkosz; Glenn Haugeberg
Journal:  Rheumatol Ther       Date:  2022-09-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.